[Sudden cardiac death and decompensation of heart failure: how to reduce the risks. A review]

M V Kuleshova1, T M Uskach2,3, O V Sapelnikov2

  • 1National Medical Research Center for High Medical Technologies - Vishnevsky Central Military Clinical Hospital.

PubMed

Insights

Sudden cardiac death and heart failure (HF) decompensation are leading causes of mortality. Implantable devices with multisensory monitoring show promise in early detection and prevention of HF decompensation, potentially reducing hospitalizations and improving survival.

Area of Science:

  • Cardiology
  • Biomedical Engineering

Background:

  • Sudden cardiac death and heart failure (HF) decompensation are primary causes of mortality in HF patients, particularly those with reduced left ventricular ejection fraction.
  • Predicting and preventing these adverse events are critical for both medical and electrophysiological management strategies.

Purpose of the Study:

  • To review clinical studies on implantable cardioverter defibrillators (ICDs) for sudden cardiac death prevention in HF.
  • To highlight the role of multisensory monitoring in implantable devices for early detection of HF decompensation.

Main Methods:

  • Overview of clinical studies on ICDs in HF.
  • Focus on implantable devices with advanced multisensory capabilities for HF monitoring.

Main Results:

  • ICDs are established for sudden cardiac death prevention.
  • Multisensory monitoring in implantable devices enables early detection of impending HF decompensation before overt symptoms arise.

Conclusions:

  • Multisensory monitoring in implantable devices offers a novel approach to proactively manage HF.
  • This technology is expected to decrease HF exacerbations, reduce hospitalizations, and ultimately lower mortality rates in HF patients.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
652
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
294
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
278
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.1K